Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2004

View Archived Issues

Cardiac chymase: a novel target in post-MI treatment

Action of NS-8 on micturation reflex investigated in rat model

Effective local bone formation and fracture healing by CP-533536

Novel KSP inhibitors identified by Merck researchers

Roche scientists present new MAO-B inhibitors for AD and senile dementia

New antipsychotic agents with 5-HT and dopamine receptor activity

Two series of morpholine-based CCR3 antagonists under study at GSK

New protein kinase inhibitors and their use in cancer therapy reported by Cytopia

A phase III clinical trial confirms the benefits of Prialt in patients with severe chronic pain

Sertraline helps depression and quality of life after hospitalization for acute coronary syndrome

PPD amends dapoxetine license

Akzo Nobel to transfer Arixtra to Sanofi-Synthelabo

Targeted Genetics extends AIDS vaccine partnership

Ranbaxy generic minocycline hydrochloride approved for marketing

Clearance for pivotal Canadian phase IIb/III trial for Tectin

Pfizer advances Atrigel product into further clinical testing

Oraqix receives FDA approval

Nutrition 21 seeks approval of chromium picolinate health benefit claims

Approvable letter for Fortical

Phase I/II trial of MTC-MMC in NSCLC cleared to begin

Alpharma launches generic equivalent of Lotrisone

Prefilled Pegasys syringes approved by FDA

Patient testing completed in phase III Cellegesic trial

LymphoStat-B enters phase II evaluation for active rheumatoid arthritis

Memantine reported effective and safe in patients with mild to moderate Alzheimer's disease

End of patient enrollment announced for two clinical trials with Velac(R) Gel

Favrille completes enrollment in a phase II clinical trial of FavId for fNHL

Ambrisentan enters phase III clinical development

Approval granted to an expanded use of Eloxatin for metastatic colorectal cancer in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.